Q3 EPS Estimate for Cullinan Therapeutics Lifted by Analyst

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) – Equities research analysts at HC Wainwright upped their Q3 2026 earnings per share estimates for Cullinan Therapeutics in a research report issued to clients and investors on Friday, October 2nd. HC Wainwright analyst R. Burns now expects that the company will post earnings of ($0.86) per share for the quarter, up from their prior estimate of ($0.90). HC Wainwright currently has a “Buy” rating and a $35.00 price target on the stock. The consensus estimate for Cullinan Therapeutics’ current full-year earnings is ($3.06) per share. HC Wainwright also issued estimates for Cullinan Therapeutics’ Q4 2026 earnings at ($0.89) EPS, FY2026 earnings at ($3.45) EPS, Q1 2027 earnings at ($0.44) EPS, Q2 2027 earnings at ($0.92) EPS, Q3 2027 earnings at ($0.93) EPS, Q4 2027 earnings at $0.39 EPS and FY2027 earnings at ($1.81) EPS.

A number of other analysts have also weighed in on the stock. BTIG Research reaffirmed a “buy” rating and issued a $40.00 price objective on shares of Cullinan Therapeutics in a research note on Friday, September 25th. TD Cowen raised shares of Cullinan Therapeutics to a “strong-buy” rating in a research report on Monday, August 24th. Wall Street Zen lowered shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, September 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cullinan Therapeutics in a research note on Wednesday, July 8th. Finally, Wedbush lifted their price objective on shares of Cullinan Therapeutics from $39.00 to $42.00 and gave the company an “outperform” rating in a report on Thursday, August 13th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $33.71.

Cullinan Therapeutics Trading Up 1.3%

CGEM opened at $16.25 on Tuesday. Cullinan Therapeutics has a 12-month low of $5.71 and a 12-month high of $23.19. The business’s fifty day simple moving average is $19.48 and its 200-day simple moving average is $16.78. The company has a market capitalization of $1.05 billion, a price-to-earnings ratio of -5.24 and a beta of -0.05.

Cullinan Therapeutics (NASDAQ:CGEM) last released its quarterly earnings data on Thursday, August 6th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.80) by ($0.01).

Institutional Trading of Cullinan Therapeutics

A number of institutional investors have recently modified their holdings of the company. BlackRock Inc. bought a new position in shares of Cullinan Therapeutics during the 2nd quarter worth approximately $95,289,000. Blue Owl Capital Holdings LP acquired a new stake in Cullinan Therapeutics in the second quarter valued at approximately $28,039,000. Dimensional Fund Advisors LP grew its holdings in Cullinan Therapeutics by 6.7% in the first quarter. Dimensional Fund Advisors LP now owns 906,028 shares of the company’s stock worth $12,870,000 after purchasing an additional 57,259 shares during the last quarter. Boone Capital Management LLC purchased a new position in Cullinan Therapeutics in the second quarter worth $12,828,000. Finally, Boothbay Fund Management LLC acquired a new position in shares of Cullinan Therapeutics during the fourth quarter worth $12,803,000. 86.31% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Cullinan Therapeutics news, insider Jennifer Michaelson sold 8,000 shares of Cullinan Therapeutics stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $21.57, for a total value of $172,560.00. Following the transaction, the insider owned 158,844 shares in the company, valued at $3,426,265.08. The trade was a 4.79% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 8.60% of the stock is currently owned by insiders.

More Cullinan Therapeutics News

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: HC Wainwright raised its EPS estimates across several periods, including Q3 2026 to $(0.86) from $(0.90), Q4 2026 to $(0.89) from $(0.93), and FY2026 to $(3.45) from $(3.53). The firm also sharply improved its FY2027 forecast to a $(1.81) loss from $(3.89), with its model now projecting positive EPS of $0.39 in Q4 2027. The revisions suggest improving expectations for Cullinan’s earnings trajectory and supported the stock’s advance. HC Wainwright Has Optimistic Opinion of CGEM Q3 Earnings
• Neutral Sentiment: Despite the upward estimate revisions, Cullinan is still expected to report losses in most quarters, including a $(3.45) per-share loss for FY2026 and a $(1.81) loss for FY2027. The company’s current-year consensus forecast remains a $(3.08) per-share loss, so investors will likely continue focusing on clinical progress, cash resources and the path toward profitability.
• Negative Sentiment: HC Wainwright’s improved outlook does not eliminate near-term earnings risk; the company remains unprofitable and its shares were still trading below their 50-day moving average, indicating that broader investor confidence has not fully recovered.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer and autoimmune diseases. The company uses a portfolio-based approach to advance targeted therapies and immune-modulating treatments intended to address significant unmet medical needs.

Cullinan’s pipeline includes zovoltamab brengitecan (CLN-978), an investigational CD19-directed T-cell engager being studied in B-cell malignancies and autoimmune conditions, and CLN-619, an investigational antibody designed to target MICA and MICB proteins and stimulate anti-tumor immune responses.